SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age-related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome.
Intended Use
This product is intended strictly for laboratory research purposes only. It is not approved for human or animal use and must not be used in food, supplements, pharmaceuticals, or cosmetic applications.
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age-related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome.
Intended Use
This product is intended strictly for laboratory research purposes only. It is not approved for human or animal use and must not be used in food, supplements, pharmaceuticals, or cosmetic applications.
Image 1 of 2
Image 2 of 2
